newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney